2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4507 Number of lines of therapy over time in CLL/SLL: Trends and predictors from 20 years of US real-world data

Sameer A. Parikh, MBBS, Moshe Levy, MD2, Naleen Raj Bhandari, Ph.D3, Jacob Ambrose, MS4, Erin Lampson, MD5, Amanda M Seyerle6, Eric Hansen, MS7, Inhye E Ahn, MD8, Tara M Graff, DO,MS9, Katherine B Winfree, PhD10, Christina M Zettler, MPH11, Bita Fakhri, MD, MPH12, Mohsen Soltanifar, PhD13, Ian W. Flinn, MD, PhD14, Ching-Kun Wang, MD15, Sarang Abhyankar, MD, MS16, Paolo Abada, MD, PhD17, Deborah Stephens, DO18
1 Mayo Clinic, Rochester, Minnesota, United States
2 Baylor Scott & White Research Institute, Dallas, Texas, United States
3 Eli Lilly and Company, Indianapolis, Indiana, United States
4 Verana Health, San Francisco, California, United States
5 Eli Lilly and Company, Indianapolis, Indiana, United States
6 Verana Health, San Francisco, California, United States
7 Verana Health, San Francisco, California, United States
8 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
9 Mission Cancer and Blood, Des Moines, Iowa, United States
10 Eli Lilly and Company, Indianapolis, Indiana, United States
11 Verana Health, San Francisco, California, United States
12 Stanford University School of Medicine, Stanford, California, United States
13 IQVIA Inc, Mississauga, Ontario, Canada
14 Tennessee Oncology and OneOncology, Nashville, Tennessee, United States
15 Verana Health, San Francisco, California, United States
16 Eli Lilly and Company, Indianapolis, Indiana, United States
17 Eli Lilly and Company, Indianapolis, Indiana, United States
18 University of North Carolina, Chapel Hill, North Carolina, United States

Background: Targeted therapies have transformed the CLL/SLL treatment (tx) landscape, and in specific populations have been associated with long-term survival similar to people without CLL/SLL. Impact of these outcomes on the total lines of therapy (LoTs) received in real-world (RW) practice is not well studied. This retrospective analysis characterized tx pattern and shifts in total LoTs received over time and identified the associated factors.

Methods: Using the deidentified US COTA EHR-derived database, adults diagnosed with CLL/SLL between JAN2006–DEC2023 who received ≥1LoT were analyzed in R4.6.0 (data cutoff: MAR2026). Baseline characteristics, first-line (1L) and 2L tx patterns were described overall, by practice setting, and diagnosis (dx) era. Baseline factors associated with receipt of 1–2LoTs (vs ≥3) were assessed using multivariable logistic regression at landmark timepoints: 3, 5, 10, and 15 years (y). Each analysis was restricted to patients (pts) who achieved the landmark timepoint or died at/prior to it. Odds ratio (OR) and 95%CI were estimated (p≤0.05 for statistical significance). Overall survival (OS) was described using the Kaplan-Meier method.

Results: Among 4134 pts, median (m) age at index (1L start) was 68y (60–76) and 76% (n=3139) were treated in community settings. Among pts with available data at index, 15% (n=361/2462) had known del(17p)/TP53 aberration and 60% (n=754/1249) had unmutated IGHV. mFollow-up (IQR) from index was 5y (2.4–8.0); 52% (n=2141) received only 1LoT, 26% (n=1081) only 2LoTs, and 22% (n=912) ≥3LoTs. Common 1L txs were chemoimmunotherapy (CIT); 38%, covalent BTKi (cBTKi) monotherapy (mono); 29%, aCD20mab mono; 9%, BCL2i+aCD20mab; 5%, and cBTKi+aCD20mab; 3%. Common tx among pts receiving 2L (n=1993) were cBTKi mono; 37%, CIT; 24%, and BCL2i+aCD20mab; 8%. Tx patterns were similar by practice settings. By end of follow-up, 1530 pts (37%) died (mAge at death: 78y [70-85]; mLoTs received: 2 [1–3]); mOS (95%CI) from index was 9.8y (9.4–10.3). In adjusted landmark analyses at 3 (n=3332), 5 (n=2855), 10 (n=1917), and 15y (n=1598), receipt of targeted 1L therapy vs CIT (OR range: 2.7–4.1 across timepoints, all p<0.001) was the strongest factor independently associated with higher odds of receiving 1–2LoTs. Additionally, older age at index (1.02–1.03 per 1y-increment, all p<0.001), longer time from dx to index (1.11–1.15 per 1y-increment, all p<0.001), presence of diabetes (1.45–1.75, all p≤0.009), and renal disease (2.09–2.16, all p≤0.016, excluding 15y [OR=1.87, p=0.068]) were independently associated with higher odds of receiving 1–2LoTs. In contrast, presence of del(17p)/TP53 aberration (0.55-0.63, all p≤0.014, excluding 10y [OR=0.63] and 15y [OR=0.63, both p≤0.072]) and unmutated IGHV status (0.33–0.5, all p≤0.032) were independently associated with lower odds of receiving 1–2LoTs. Findings were broadly consistent across practice settings.

Distribution of pts across dx eras was 13% (2006–08), 19% (2009–11), 21% (2012–14), 23% (2015–17), 16% (2018–20), and 8% (2021–23). mFollow-up from index was 8, 7, 6, 5, 4, and 2y, respectively. The proportion of pts receiving 1–2LoTs was 62%, 66%, 77%, 83%, 91%, and 95%, with shorter follow-up in recent eras. cBTKi-based 1L tx was 8% in 2006–08 and 63% in 2021–23; BCL2i+aCD20mab use was 1% and 17%, respectively, with increasing trends in txs over time.

Conclusion: In this analysis spanning 20y of RW practice, 62% of pts diagnosed in 2006–08 received 1–2LoTs vs 95% in 2021–23, with an overall proportion of 78%, reflecting both the transition from CIT-dominant to targeted-tx-dominant 1L practice and longer follow-up in earlier cohorts. The association between 1L targeted tx and fewer LoTs strengthened across landmark timepoints, underscoring a benefit of early targeted tx on cumulative LoTs received. Dx of chronic comorbidities including diabetes and renal disease were also associated with fewer LoTs received. Presence of high-risk disease features was associated with more LoTs received. These findings, consistent across practice settings, reinforce that many pts with CLL/SLL may have no more than two tx decisions in their disease course, whether due to durable disease control and/or competing mortality, highlighting that early tx selection should account for both efficacy and practical considerations such as safety and quality of life. Longer observation of recently diagnosed pts will help to further characterize tx burden in the recent era.
Deborah Stephens, DO: Beigene - Honoraria; AstraZeneca - Honoraria; BMS - Honoraria; Celgene - Honoraria; Janssen - Honoraria; Genentech - Honoraria; Pharmacyclics - Honoraria; Eli Lilly - Honoraria; AbbVie - Honoraria; Genentech - Research Funding; Novartis - Research Funding; BMS - Research Funding; BeOne - Research Funding; AstraZeneca - Research Funding; Pharmacyclics - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)